Miriyam Ghali

Ms. Miriyam Ghali


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
ILIenglam Lei
Ienglam Lei
WHWei Huang
Wei Huang
pierre-emmanuel nolypierre-emmanuel noly
pierre-emmanuel noly
SNSuyash Naik
Suyash Naik
MGMiriyam Ghali
Miriyam Ghali
PTPaul C. Tang
Paul C. Tang
Preservation quality of donor hearts is a key determinant of transplant success. Preservation duration beyond 4 hours is associated with primary graft dysfunction (PGD). Given transport time constraints, geographical limitations exist for donor-recipient matching, leading to donor heart underutilization. Here, we showed that metabolic reprogramming through up-regulation of the enzyme immune response gene 1 (IRG1) and its product itaconate improved heart function after prolonged preservation. Irg1 transcript induction was achieved by adding the histone deacetylase (HDAC) inhibitor valproic acid (VPA) to a histidine-tryptophan-ketoglutarate solution used for donor heart preservation. VPA increased acetylated H3K27 occupancy at the IRG1 enhancer and IRG1 transcript expression in human donor hearts. IRG1 converts aconitate to itaconate, which has both anti-inflammatory and antioxidant properties. Accordingly, our studies showed that Irg1 transcript up-regulation by VPA treatment increased nuclear translocation of nuclear factor erythroid 2–related factor 2 (Nrf2) in mice, which was accompanied by increased antioxidant protein expression [hemeoxygenase 1 (HO1) and superoxide dismutase 1 (SOD1)]. Deletion of Irg1 in mice (Irg1 −/− ) negated the antioxidant and cardioprotective effects of VPA. Consistent with itaconate’s ability to inhibit succinate dehydrogenase, VPA treatment of human hearts increased itaconate availability and reduced succinate accumulation during preservation. VPA similarly increased IRG1 expression in pig donor hearts and improved its function in an ex vivo cardiac perfusion system both at the clinical 4-hour preservation threshold and at 10 hours. These results suggest that augmentation of cardioprotective immune-metabolomic pathways may be a promising therapeutic strategy for improving donor heart function in transplantation.

3 October 2022 in JBJS Open Access
Verified
Journal Article
Open access
RMRidge Maxson
Ridge Maxson
MGMiriyam Ghali
Miriyam Ghali
CLChristopher R. Leland
Christopher R. Leland
GTGregory R. Toci
Gregory R. Toci
CMClaire McDaniel
Claire McDaniel
AAAmiethab A. Aiyer
Amiethab A. Aiyer
Background: The purpose of this study was to assess the influence of the COVID-19 pandemic on the 2021 orthopaedic surgery residency match outcomes. Because in-person away rotations and interviews were canceled during the 2020 to 2021 application cycle, we hypothesized that applicants would match at their home program at a higher rate in 2021 than in previous years. Methods: We queried allopathic orthopaedic surgery residency websites and social media accounts for names of residents and medical school information for cohorts matching from 2017 through 2021. To assess availability of and participation in virtual away rotations, we administered a survey to Accreditation Council for Graduate Medical Education–accredited allopathic orthopaedic surgery residency programs. The primary outcome was the annual proportion of applicants matching at the program affiliated with their medical school (“home program”). Subgroup analyses were stratified by Doximity reputation ranking and availability of a virtual away rotation. Results: We identified 2,632 residents who matched between 2017 and 2020 and 698 residents who matched in 2021. Overall home program match rate and likelihood of home matching were higher in 2021 compared with 2017 to 2020 (28% vs. 20%; odds ratio [OR] = 1.51, 95% confidence interval [CI] 1.24-1.82, p < 0.001). The increase in the home match rate at programs ranked in the top 30 (27% vs. 20%, p = 0.034) was similar to the increase at programs ranked outside the top 30 (28% vs. 20%, p < 0.001). Of the 66 (48%) programs that responded to the survey, 16 (24%) offered a virtual away rotation. Programs with a higher Doximity ranking were more likely than lower-ranked programs to offer a virtual away rotation (OR = 6.75, 95% CI 1.95-23.4, p = 0.003). Home match rates did not differ significantly between programs that offered a virtual away rotation and those that did not (26% vs. 32%, p = 0.271). Conclusions: A higher proportion of orthopaedic surgery residency applicants matched at their home program in 2021 compared with previous years. Limitations on in-person activities due to the COVID-19 pandemic may have contributed to this rise. Level of Evidence: N/A.

16 October 2025 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
MGMiriyam Ghali
Miriyam Ghali
NSNicolette Ann Schurhoff
Nicolette Ann Schurhoff
WCWilliam Cade
William Cade
NPNikhil Patel
Nikhil Patel
SDSeth D. Dodds
Seth D. Dodds
DMDanielle C. Marshall
Danielle C. Marshall
Background: Intimate partner violence (IPV) is estimated to affect 15% to 71% of women and 10% to 14% of men in the United States, with musculoskeletal injuries being the second most common manifestation of IPV. Existing research on IPV has largely been conducted in White, English-speaking women, with little data on IPV in men, socioeconomically and ethnically diverse populations, and nonbinary individuals. Moreover, the scope of outcome measures has been limited, with few studies evaluating patient-reported and long-term outcomes in this area. Question/purpose: Do patients who screen positive for IPV after injury report lower health-related quality of life compared with those who screen negative in an orthopaedic hand and upper extremity clinic? Methods: A prospective study was completed between August 2022 to May 2023 at an orthopaedic hand clinic within a large urban Level 1 trauma hospital. Inclusion criteria were all patients age 18 years and older who presented with acute upper extremity injury and had the ability to complete forms in English, Haitian Creole, or Spanish independently. We invited 713 patients to participate; 25% (178) did not consent, and data from 5% (35) were excluded because the data were incomplete, leaving a total enrollment of 500 patients. Fifty-eight percent (289 of 500) of the participants were men, 71% (357 of 500) were Hispanic, 48% (233 of 482) were not US citizens, 47% (236 of 498) were single, and 34% (170 of 500) were without healthcare insurance; the study group had a mean age of 45 years. Participants were screened for IPV using the Direct IPV screening tool and Extended Hurt, Insult, Threaten, Scream (E-HITS) tools. Participants then completed a study-specific clinical survey and the three-level EQ-5D-3L survey, a validated 5-question patient-reported outcome measure that assesses health-related quality of life. The overall calculated index ranges from 5 (best health) to 15 (worst health), with prior research reporting a minimum clinically important difference (MCID) of 0.074. Kruskal-Wallis tests were used for continuous and categorical data, chi-square or Fisher exact tests for categorical comparisons, and a logistic regression analysis to identify factors influencing positive IPV screening. We reported both unadjusted and adjusted ORs to assess variable influence. Results: The proportion of patients who screened positive for experiencing IPV within their lifetime in our study was 24% (120 of 500). Patients who screened positive for IPV reported lower health-related quality of life compared with those who screened negative in addition to reported differences in EQ-5D-3L scores (median 8.0 [IQR 6.0 to 10.0]) compared with those who did not report IPV (median 7.0 [IQR 6.0 to 9.0]; p = 0.003). The difference in EQ-5D-3L scores between positive and negative IPV disclosure groups, respectively, also surpassed the accepted MCID within the disability subcategories of mobility (mean ± SD 1.4 ± 0.6 versus 1.2 ± 0.5; p = 0.04), pain/discomfort (2.1 ± 0.7 versus 1.8 ± 0.6; p = 0.006), and anxiety/depression (1.9 ± 0.7 versus 1.4 ± 0.6; p < 0.001). We found no difference in the EQ-5D-3L disability subcategories of self-care (1.4 ± 0.6 versus 1.4 ± 0.6; p = 0.88) and usual activities (1.7 ± 0.6 versus 1.7 ± 0.7; p = 0.74) reported between groups. Conclusion: To our knowledge, this is the first study that has been performed in a predominantly non-White, mixed-gender, socioeconomically underserved population. This study demonstrates that current standardized screening tools for IPV can be effectively used in a more general population. This screening is important, as our study found that patients who disclose IPV reported greater disability than their counterparts with EQ-5D-3L scores that surpassed the MCID both overall and within several subcategories. Based on these discoveries, orthopaedic surgeons might consider screening prospectively for IPV in all patients who present with hand and upper extremity injuries so that prompt referral to support services can be made. This may improve a patient’s likelihood of obtaining satisfactory health outcomes after injury. Level of Evidence: Level II, therapeutic study.